# A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Source: https://onco.cc/trials/nct06356311/  
OnCo record `nct06356311` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab tirumotecan, FOLFIRI, Paclitaxel / nab-paclitaxel in oesophageal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) is a phase 3 interventional study registered as NCT06356311 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2024-05-03 and due to reach its primary completion in 2027-01-04. Interventions recorded: Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel. Conditions listed: Gastroesophageal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06356311
- Phase: 3
- Setting: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT06356311: https://clinicaltrials.gov/study/NCT06356311

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06356311.json